Robert Plenge's guest appearances

Robert Plenge

Tech Tonics

Pull Up a Chair with Dr. Freire: The COVID Conversations

Daphne Koller

Michelle Meyer

Brian Smith

Francis Collins

Stephanie Tilenius

Janet Woodcock

Dave Albert

Will Ahmed

Toby Cosgrove

Kevin Lyman

Madeline Bell

Rasu Shrestha

Brennan Spiegel

Matthew Holt

Martin Kelly

OwlTail

Dr. Freire hosts an engaging and informative conversation with two scientists from Bristol Myers Squibb: Dr. Mary Beth Harler and Dr. Robert Plenge.  Learn how treatments for COVID-19 are addressed along the continuum from initial work in the lab to patient care. Drs. Freire, Harler and Plenge also discuss the importance of looking at the biology of this virus to identify the best treatment options. Dr. Mary Beth Harler is Senior Vice President, Head of Immunology &amp; Fibrosis Development, Global Drug Development and Dr. Robert Plenge is Senior Vice President, Research &amp; Early Development and Head of the Immunology, Cardiovascular, Fibrosis, and Global Health Thematic Research Center team of Bristol Myers Squibb.

Dr. Freire hosts an engaging and informative conversation with two scientists from Bristol Myers Squibb: Dr. Mary Beth Harler and Dr. Robert Plenge.  Learn how treatments for COVID-19 are addressed along the continuum from initial work in the lab to patient care. Drs. Freire, Harler and Plenge also discuss the importance of looking at the biology of this virus to identify the best treatment options.  Dr. Mary Beth Harler is Senior Vice President, Head of Immunology &amp; Fibrosis Development, Global Drug Development and Dr. Robert Plenge is Senior Vice President, Research &amp; Early Development and Head of the Immunology, Cardiovascular, Fibrosis, and Global Health Thematic Research Center team of Bristol Myers Squibb.

Interview with Drs. Mary Beth Harler and Robert Plenge from Bristol Myers Squibb

For years, medical research seemed focused on understanding disease processes primarily through model organisms such as yeast, flies, and mice. Today’s guest, Merck’s Robert Plenge, offers the radical suggestion that with the help of emerging technology “humans serve as the best model organism for understanding human health and disease.” As a physician-scientist, trained as a clinical rheumatologist and geneticist, Robert conducted research at Boston’s Brigham and Women’s Hospital, and served as an Associate Member of the Broad Institute, before joining Merck in 2013. Still based in Boston, he’s now Vice President and Head of Translational Medicine at Merck. He also writes a popular, personal blog related to translational medicine, and is active on twitter (@rplenge). On today’s program we ask Robert how he’s managed to maintain an active social media presence while working for big pharma. We also discuss his transition from academic medicine to industry and, most importantly, learn how he’s applying his passion for “causal human biology” to turn data into drugs. This episode of Tech Tonics is sponsored by DNAnexus, the secure and compliant cloud platform that enables enterprise users to analyze, collaborate around, and integrate massive amounts of genetic and other health data.

For years, medical research seemed focused on understanding disease processes primarily through model organisms such as yeast, flies, and mice. Today’s guest, Merck’s Robert Plenge, offers the radical suggestion that with the help of emerging technology “humans serve as the best model organism for understanding human health and disease.” As a physician-scientist, trained as a clinical rheumatologist and geneticist, Robert conducted research at Boston’s Brigham and Women’s Hospital, and served as an Associate Member of the Broad Institute, before joining Merck in 2013. Still based in Boston, he’s now Vice President and Head of Translational Medicine at Merck. He also writes a popular, personal blog related to <a href="http://www.plengegen.com" rel="nofollow" target="_blank">translational medicine</a>, and is active on twitter (@rplenge). On today’s program we ask Robert how he’s managed to maintain an active social media presence while working for big pharma. We also discuss his transition from academic medicine to industry and, most importantly, learn how he’s applying his passion for “causal human biology” to turn data into drugs. This episode of Tech Tonics is sponsored by <a href="https://www.dnanexus.com" rel="nofollow" target="_blank">DNAnexus</a>, the secure and compliant cloud platform that enables enterprise users to analyze, collaborate around, and integrate massive amounts of genetic and other health data.

Tech Tonics: Merck’s Robert Plenge on Human Biology and Social Media